HAS2 and breast cancer: In contrast to HAS2 or hyaluronan up-regulation in BrCa as reported before (Auvinen et al., 2014), we found a significant decrease of HAS2 expression after endocrine resistance is acquired in estrogen receptor-positive (ER+) breast cancer cells, with a predictable down expression of ER.